MENU
STVN
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

STVN stock forecast, quote, news & analysis

Stevanato Group is a provider of glass and polymer drug containment, drug delivery, and diagnostic solutions to the pharmaceutical and life sciences industries... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
STVN
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for STVN with price predictions
Oct 07, 2026

STVN sees MACD Histogram just turned negative

STVN saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on September 24, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 56 instances where the indicator turned negative. In 46 of the 56 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 82%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on STVN as a result. In 74 of 95 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.

STVN moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for STVN crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 75%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where STVN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for STVN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +5.25% 3-day Advance, the price is estimated to grow further. Considering data from situations where STVN advanced for three days, in 246 of 308 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

STVN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 153 of 158 cases where STVN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. STVN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 64 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.317) is normal, around the industry mean (5.020). P/E Ratio (38.404) is within average values for comparable stocks, (166.342). Projected Growth (PEG Ratio) (1.538) is also within normal values, averaging (4.143). Dividend Yield (0.003) settles around the average of (0.005) among similar stocks. P/S Ratio (4.348) is also within normal values, averaging (56.876).

The Tickeron SMR rating for this company is 74 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. STVN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.03B. The market cap for tickers in the group ranges from 126 to 146.54B. ISRG holds the highest valuation in this group at 146.54B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was -3%. For the same Industry, the average monthly price growth was -6%, and the average quarterly price growth was 12%. ZJYL experienced the highest price growth at 11%, while NNNN experienced the biggest fall at -22%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was -19%. For the same stocks of the Industry, the average monthly volume growth was 19% and the average quarterly volume growth was 9%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 57
P/E Growth Rating: 58
Price Growth Rating: 56
SMR Rating: 81
Profit Risk Rating: 96
Seasonality Score: 12 (-100 ... +100)
STVN sees MACD Histogram just turned negative